Navigation Links
PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022

NEW YORK, Sept. 12, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022

Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

The Indian NSCLC market has been especially difficult for drug companies to penetrate, and the market revolves almost exclusively around generics. The market is dominated by generic chemotherapies including pemetrexed (Alimta) as well as the generic targeted therapies erlotinib (Tarceva) and gefitinib (Iressa).


- Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting India NSCLC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for NSCLC- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India.1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 102.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology and Histology 133.1.3 NSCLC Biomarkers 143.1.4 Quality of Life 153.2 Symptoms 164 Disease Management 184.1 Treatment Overview 184.1.1 Diagnosis 194.1.2 Clinical Staging 204.1.3 Screening and Early Detection 224.1.4 Localized Procedures and Therapies 234.1.5 Systemic Chemotherapy 244.1.6 Targeted Therapy 254.2 India 274.2.1 Diagnosis 274.2.2 Clinical Practice 285 Competitive Assessment 305.1 Overview 305.2 Strategic Competitor Assessment 315.3 Product Profiles – Major Brands, Chemotherapies 335.3.1 Alimta (pemetrexed disodium) 335.4 Product Profiles – Major Brands, Targeted Therapies 375.4.1 Iressa (gefitinib) 375.4.2 Tarceva (erlotinib hydrochloride) 425.4.3 Xalkori (crizotinib) 485.4.4 Avastin (bevacizumab) 526 Opportunity and Unmet Need 566.1 Overview 566.2 Improved Overall Survival and Less Toxicity 576.3 Treatments for Patients with Acquired TKI Resistance 586.4 Better Treatment Options for Squamous Patients 596.5 Preventing Relapse or Recurrence 596.6 More Efficacious Second-Line Therapies 606.7 Increased Availability of Mutation Testing 606.8 More Cost-Effective Therapies 616.9 Unmet Needs Gap Analysis 627 Pipeline Assessment 667.1 Overview 667.2 Promising Drugs in Clinical Development 667.2.1 nintedanib (BIBF1120) 707.2.2 Gilotrif (afatinib) 747.2.3 dacomitinib (PF-00299804) 807.2.4 LDK378 848 Market Outlook 908.1 India 908.1.1 Forecast 908.1.2 Key Events 948.1.3 Drivers and Barriers 949 Appendix 969.1 Bibliography 969.2 Abbreviations 1089.3 Methodology 1129.4 Forecasting Methodology 1129.4.1 Number of NSCLC Patients Currently Seeking Treatment 1129.4.2 Percent Drug-treated Patients 1139.4.3 Drugs Included in Each Therapeutic Class 1139.4.4 Launch and Patent Expiry Dates 1149.4.5 General Pricing Assumptions 1149.4.6 Individual Drug Assumptions 1179.4.7 Generic Erosion 1219.4.8 Pricing of Pipeline Agents 1229.5 Physicians and Specialists Included in This Study 1249.6 Survey of Prescribing Physicians 1269.7 About the Authors 1279.7.1 Authors 1279.7.2 Epidemiologists 1289.7.3 Global Head of Healthcare 1299.8 About GlobalData 1309.9 Disclaimer 130

1.1 List of Tables Table 1: Symptoms of Disease NSCLC 17

Table 2: Treatment Guidelines for NSCLC 19

Table 3: Stage Definitions for NSCLC 21

Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27

Table 5: Leading Treatments for NSCLC 33

Table 6: Product Profile – Alimta (pemetrexed disodium) 35

Table 7: Alimta SWOT Analysis, 2013 37

Table 8: Product Profile – Iressa (gefitinib) 39

Table 9: Iressa SWOT Analysis, 2013 42

Table 10: Product Profile – Tarceva (erlotinib hydrochloride) 44

Table 11: Tarceva SWOT Analysis, 2013 47

Table 12: Product Profile – Xalkori (crizotinib) 49

Table 13: Xalkori SWOT Analysis, 2013 52

Table 14: Product Profile – Avastin (bevacizumab) 53

Table 15: Avastin SWOT Analysis, 2013 55

Table 16: Overall Unmet Needs – Current Level of Attainment 57

Table 17: Clinical Unmet Needs – Gap Analysis, 2013 63

Table 18: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013 67

Table 19: NSCLC – Phase III Pipeline, 2013 68

Table 20: NSCLC – Advantages and Disadvantages of Therapeutic Classes 69

Table 21: Product Profile – nintedanib (BIBF-1120) 70

Table 22: nintedanib SWOT Analysis, 2013 74

Table 23: Product Profile – Gilotrif (afatinib) 75

Table 24: Gilotrif SWOT Analysis, 2013 79

Table 25: Product Profile – dacomitinib (PF-00299804) 80

Table 26: dacomitinib SWOT Analysis, 2013 84

Table 27: Product Profile – LDK378 85

Table 28: LDK378 SWOT Analysis, 2013 89

Table 29: Sales Forecasts ($m) for NSCLC in India, 2012-2022 92

Table 30: Key Events Impacting Sales for NSCLC in India, 2012–2022 94

Table 31: NSCLC Market in India – Drivers and Barriers, 2012–2022 94

Table 32: Five Year Prevalence 113

Table 33: Key Launch Dates 114

Table 34: Physicians Surveyed by Country 126

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022 69Figure 2: Sales for NSCLC in India by Drug, 2012–2022 93

To order this report: PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022

Contact Clare:
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
7. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
8. Varian Medical Systems to Support an NCI-Sponsored Phase III Study Comparing Radiosurgery with Surgery for the Treatment of Early-Stage High-Risk, Operable Non-Small Cell Lung Cancer
9. Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
10. The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
11. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology:
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
Breaking Medicine News(10 mins):